More than 700,000 Americans had used Bayer’s cholesterol-lowering medication, Baycol, before it was withdrawn from the market in August 2001.  Baycol was linked to an increased risk of rhaddomyolysis. Rhaddomyolysis is a very serious condition characterized by the breakdown of muscle tissue in the body, which can cause renal failure and death. After many reports of this condition and over 100 deaths, Bayer had to pull the drug off the market. Baycol is no longer sold anywhere in the world.

The litigation focused on Bayer’s early knowledge of Baycol being much more potent than other statins and its much higher risk to patients. Bayer documents reveal the company was desperate for Baycol to become a blockbuster drug that could generate millions of dollars of income for their pharmaceutical division.

More than 3,000 rhaddomyolysis claims have been settled since the withdrawal with over $1 billion paid to those injured. Beasley Allen personally handled over 80 million dollars of these claims.

New York Times
Wall Street Journal

Andy Birchfield, Beasley Allen Attorney
Andy Birchfield

Andy is the firm's Mass Torts Section Head.

Frank Woodson
Frank Woodson

Frank was appointed to the Plaintiffs Steering Committee for Lipitor litigation.

Melissa Prickett, Beasley Allen Attorney
Melissa Prickett

Melissa serves as the director of operations for Beasley Allen Law Firm’s Mass Torts Section.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Confidence and Integrity

Thank you for a wonderful job you did on our case. I have always enjoyed working with Beasley Allen lawyers because of the confidence and integrity that is shown to clients and colleagues alike.

—Allen Clardy, The Clardy Law Firm